![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Nucryst Pharmaceuticals - Common Shares (MM) | NASDAQ:NCST | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.77 | 0 | 01:00:00 |
As filed with the Securities and Exchange Commission on February 8, 2010
Registration No. 333-150921
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
POST-EFFECTIVE AMENDMENT NO. 2
TO
FORM S-8
REGISTRATION STATEMENT UNDER THE
SECURITIES ACT OF 1933
NUCRYST Pharmaceuticals Corp.
(Exact Name of Registrant as Specified in its Charter)
Alberta, Canada | Not applicable | |
(State or Other Jurisdiction of Incorporation or Organization) |
(I.R.S. Employer Identification No.) |
NUCRYST Pharmaceuticals Corp. 101 College Road East Princeton, New Jersey |
08540 | |
(Address of Principal Executive Offices) | (Zip Code) |
NUCRYST Pharmaceuticals Corp.
1998 Equity Incentive Plan (as amended)
(Full Title of the Plan)
Carol L. Amelio
Vice President General Counsel
NUCRYST Pharmaceuticals Corp.
101 College Road East
Princeton, New Jersey
(Name and Address of Agent For Service)
(609) 228-8210
(Telephone Number, Including Area Code, of Agent For Service)
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.
Large accelerated filer |
¨ | Accelerated filer | ¨ | |||||||
Non-accelerated filer |
¨ | (Do not check if a smaller reporting company) | Smaller reporting company | þ |
EXPLANATORY NOTE
This Post-Effective Amendment filed by NUCRYST Pharmaceuticals Corp. (the Company), deregisters all of the Companys Common Shares, no par value per share that had been registered for issuance on Form S-8 (File No. 333-150921), originally filed with the Securities and Exchange Commission on May 14, 2008 (the Registration Statement), as amended to date.
In order for the Company to file a Form 15 and suspend its duty to file reports under Sections 13 and 15(d) of the Securities Exchange Act of 1934, as amended, the Registration Statement is hereby amended to deregister any Common Shares remaining unissued under the Companys 1998 Equity Incentive Plan, as amended.
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Amendment to the registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Princeton, New Jersey on February 8, 2010.
NUCRYST PHARMACEUTICALS CORP. | ||
By: | / S / D AVID B. H OLTZ | |
David B. Holtz | ||
Interim Chief Executive Officer and Chief Financial Officer |
Pursuant to the requirements of the Securities Act of 1933, this Amendment to the registration statement has been signed by the following persons in the capacities indicated.
/ S / D AVID B. H OLTZ David B. Holtz |
Interim Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial and Accounting Officer) |
February 8, 2010 Date |
||
/ S / B ARRY M. H ECK Barry M. Heck |
Director |
February 3, 2010 Date |
||
/ S / N EIL C ARRAGHER Neil Carragher |
Director |
February 5, 2010 Date |
||
/ S / R ICHARD Z AHN Richard Zahn |
Director |
February 4, 2010 Date |
1 Year Nucryst Chart |
1 Month Nucryst Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions